BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han A, Czajkowski LM, Donaldson A, Baus HA, Reed SM, Athota RS, Bristol T, Rosas LA, Cervantes-Medina A, Taubenberger JK, Memoli MJ. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model. Clin Infect Dis 2019;69:2082-90. [PMID: 30770534 DOI: 10.1093/cid/ciz141] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Park J, Fong Legaspi SL, Schwartzman LM, Gygli SM, Sheng Z, Freeman AD, Matthews LM, Xiao Y, Ramuta MD, Batchenkova NA, Qi L, Rosas LA, Williams SL, Scherler K, Gouzoulis M, Bellayr I, Morens DM, Walters K, Memoli MJ, Kash JC, Taubenberger JK. An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. Sci Transl Med 2022;14:eabo2167. [DOI: 10.1126/scitranslmed.abo2167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Choy RKM, Bourgeois AL, Ockenhouse CF, Walker RI, Sheets RL, Flores J. Controlled Human Infection Models To Accelerate Vaccine Development. Clin Microbiol Rev. [DOI: 10.1128/cmr.00008-21] [Reference Citation Analysis]
3 Motallebi S, Cheung RC, Mohit B, Shahabi S, Alishahi Tabriz A, Moattari S. Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths. American Journal of Preventive Medicine 2021. [DOI: 10.1016/j.amepre.2021.09.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lynch SA, Subbarao K, Mahanty S, Barber BE, Roulis EV, van der Hoek L, McCarthy JS, Spann KM. Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia. Viruses 2021;13:1618. [PMID: 34452482 DOI: 10.3390/v13081618] [Reference Citation Analysis]
5 Schrock JM, Ryan DT, Saber R, Benbow N, Vaught LA, Reiser N, Velez MP, Hsieh R, Newcomb M, Demonbreun AR, Mustanski B, McNally EM, D'Aquila R, McDade TW. Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults. Open Forum Infect Dis 2021;8:ofab244. [PMID: 34316503 DOI: 10.1093/ofid/ofab244] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lin X, Lin F, Liang T, Ducatez MF, Zanin M, Wong SS. Antibody Responsiveness to Influenza: What Drives It? Viruses 2021;13:1400. [PMID: 34372607 DOI: 10.3390/v13071400] [Reference Citation Analysis]
7 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Reference Citation Analysis]
8 Goyal A, Reeves DB, Thakkar N, Famulare M, Cardozo-Ojeda EF, Mayer BT, Schiffer JT. Slight reduction in SARS-CoV-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation. Sci Rep 2021;11:11838. [PMID: 34088959 DOI: 10.1038/s41598-021-91338-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Cortese M, Sherman AC, Rouphael NG, Pulendran B. Systems Biological Analysis of Immune Response to Influenza Vaccination. Cold Spring Harb Perspect Med 2021;11:a038596. [PMID: 32152245 DOI: 10.1101/cshperspect.a038596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Drossinos Y, Weber TP, Stilianakis NI. Droplets and aerosols: An artificial dichotomy in respiratory virus transmission. Health Sci Rep 2021;4:e275. [PMID: 33977157 DOI: 10.1002/hsr2.275] [Reference Citation Analysis]
11 Manheim D, Wiȩcek W, Schmit V, Morrison J; 1Day Sooner Research Team. Exploring Risks of Human Challenge Trials For COVID-19. Risk Anal 2021;41:710-20. [PMID: 33942351 DOI: 10.1111/risa.13726] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wong SS, Oshansky CM, Guo XJ, Ralston J, Wood T, Reynolds GE, Seeds R, Jelley L, Waite B, Jeevan T, Zanin M, Widdowson MA, Huang QS, Thomas PG, Webby RJ; SHIVERS Investigation Team. Activated CD4+ T cells and CD14hiCD16+ monocytes correlate with antibody response following influenza virus infection in humans. Cell Rep Med 2021;2:100237. [PMID: 33948570 DOI: 10.1016/j.xcrm.2021.100237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, Ghisetti V, Bonora S, Di Perri G, Calcagno A. On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. Front Microbiol 2021;12:646679. [PMID: 33815334 DOI: 10.3389/fmicb.2021.646679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Spinelli MA, Glidden DV, Gennatas ED, Bielecki M, Beyrer C, Rutherford G, Chambers H, Goosby E, Gandhi M. Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. Lancet Infect Dis 2021;21:e296-301. [PMID: 33631099 DOI: 10.1016/S1473-3099(20)30982-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
15 Le Sage V, Jones JE, Kormuth KA, Fitzsimmons WJ, Nturibi E, Padovani GH, Arevalo CP, French AJ, Avery AJ, Manivanh R, Mcgrady EE, Bhagwat AR, Lauring AS, Hensley SE, Lakdawala SS, Thomas PG. Pre-existing heterosubtypic immunity provides a barrier to airborne transmission of influenza viruses. PLoS Pathog 2021;17:e1009273. [DOI: 10.1371/journal.ppat.1009273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses 2021;13:281. [PMID: 33670360 DOI: 10.3390/v13020281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Yang JY, Parkins MD, Canakis A, Aroniadis OC, Yadav D, Dixon RE, Elmunzer BJ, Forbes N; DMC-19 Study Group and the North American Alliance for the Study of Digestive Manifestations of COVID-19. Outcomes of COVID-19 Among Hospitalized Health Care Workers in North America. JAMA Netw Open 2021;4:e2035699. [PMID: 33507259 DOI: 10.1001/jamanetworkopen.2020.35699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Han A, Taubenberger JK, Memoli MJ. Reply to Bernstein, Atmar, and Hoft. Clin Infect Dis 2020;71:3013-4. [PMID: 32206777 DOI: 10.1093/cid/ciaa279] [Reference Citation Analysis]
19 Spinola SM, Broderick C, Zimet GD, Ott MA. Human Challenge Studies With Wild-Type Severe Acute Respiratory Sydrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research. Open Forum Infect Dis 2021;8:ofaa615. [PMID: 33506070 DOI: 10.1093/ofid/ofaa615] [Reference Citation Analysis]
20 Burgess S, Smith D, Kenyon JC, Gill D. Lightening the viral load to lessen covid-19 severity. BMJ 2020;371:m4763. [PMID: 33303483 DOI: 10.1136/bmj.m4763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
21 Kuiper VP, Rosendaal FR, Kamerling IMC, Visser LG, Roestenberg M. Assessment of Risks Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Experimental Human Infection Studies. Clin Infect Dis 2021;73:e1228-34. [PMID: 33249450 DOI: 10.1093/cid/ciaa1784] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Van Damme W, Dahake R, van de Pas R, Vanham G, Assefa Y. COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics? Med Hypotheses 2021;146:110431. [PMID: 33288314 DOI: 10.1016/j.mehy.2020.110431] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
23 Hausdorff WP, Flores J. Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19. Int J Infect Dis 2021;103:37-41. [PMID: 33227512 DOI: 10.1016/j.ijid.2020.11.171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Xiao Y, Gouzoulis M, Lumbard K, Hunsberger S, Reed S, Athota R, Baus HA, Lwin A, Sadoff J, Taubenberger JK, Memoli MJ. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin Infect Dis 2020:ciaa1725. [PMID: 33211860 DOI: 10.1093/cid/ciaa1725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Spinola SM, Zimet GD, Ott MA, Katz BP. Human Challenge Studies Are Unlikely to Accelerate Coronavirus Vaccine Licensure Due to Ethical and Practical Issues. J Infect Dis 2020;222:1572-4. [PMID: 32845303 DOI: 10.1093/infdis/jiaa457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Du R, Cui Q, Rong L. Flu Universal Vaccines: New Tricks on an Old Virus. Virol Sin 2021;36:13-24. [PMID: 32870450 DOI: 10.1007/s12250-020-00283-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Hoffman HT, Miller RM, Walsh JE, Stegall HR, Diekema DJ. Negative pressure face shield for flexible laryngoscopy in the COVID-19 era. Laryngoscope Investig Otolaryngol 2020;5:718-26. [PMID: 32864444 DOI: 10.1002/lio2.437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Pleguezuelos O, James E, Fernandez A, Lopes V, Rosas LA, Cervantes-Medina A, Cleath J, Edwards K, Neitzey D, Gu W, Hunsberger S, Taubenberger JK, Stoloff G, Memoli MJ. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines 2020;5:22. [PMID: 32194999 DOI: 10.1038/s41541-020-0174-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
29 [DOI: 10.1101/2020.11.19.20234658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]